Could risk-based breast cancer screening replace yearly mammograms for some women?

Could breast cancer screening eventually be tailored to a woman’s personal risk instead of relying on the same schedule for everyone?

A large randomized U.S. trial known as WISDOM suggests that may be possible for some women. But the results do not mean routine yearly mammograms should be replaced right away.

What the WISDOM trial studied

The WISDOM study compared two approaches in women ages 40 to 74 who had no prior breast cancer diagnosis. One group was assigned to annual mammograms. The other got a risk assessment based on factors such as age, genes, health history, lifestyle, and breast density, and then received a screening plan matched to that risk.

According to the JAMA report and NIH summary, the risk-based approach performed similarly to annual screening on the study’s main safety measure over the follow-up period. In plain language, that is encouraging — but it is not the same as proving the two strategies will produce the same long-term results.

Why the result matters

The idea behind risk-based screening is simple: women at higher risk may benefit from closer follow-up, while women at lower risk may not need the same testing intensity every year. The NIH said the approach could reduce anxiety, costs, and unnecessary follow-up testing. The trial also suggests the model may be workable at national scale, since women from all 50 states were included and many participants in the observational arm chose the risk-based option.

That said, the study did not show a clear drop in biopsies, and screening in both groups did not always follow the assigned recommendations. Those are important caveats when interpreting the findings.

What it does not yet answer

This study is encouraging, but it does not settle the question of whether risk-based screening should become routine practice now.

Still unclear are the long-term effects on breast cancer deaths, how easy the approach would be to implement broadly, and how insurance coverage would work in everyday care. The study also does not answer whether health systems, insurers, and patients could adopt this model smoothly outside a trial setting.

Where current U.S. guidance stands

The CDC says mammography is the main screening test for most women, and the National Cancer Institute notes that breast MRI is used along with mammography for women at high risk. The American Cancer Society also emphasizes that breast cancer screening is not one-size-fits-all and that screening plans can differ by risk.

For average-risk women, current U.S. guidance still centers on mammography. For women with higher-than-average risk, clinicians may recommend a different schedule, MRI, or both.

What readers can do

Do not change your screening plan on your own because of this study. If you are due for breast cancer screening, talk with a clinician about your personal risk, your family history, and what schedule makes sense for you.

If you already know you are at higher risk, it may be worth asking whether your current plan should include MRI, a different interval, or a formal risk assessment.

For most readers, the practical takeaway is cautious optimism: risk-based screening may eventually help make breast cancer screening more precise, but regular mammography is still the standard starting point for most women in the United States.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.